Free Trial

Embecta Q3 2024 Earnings Report

Embecta logo
$19.82 -0.17 (-0.85%)
(As of 12/17/2024 ET)

Embecta EPS Results

Actual EPS
$0.74
Consensus EPS
$0.46
Beat/Miss
Beat by +$0.28
One Year Ago EPS
$0.69

Embecta Revenue Results

Actual Revenue
$272.50 million
Expected Revenue
$267.44 million
Beat/Miss
Beat by +$5.06 million
YoY Revenue Growth
-4.80%

Embecta Announcement Details

Quarter
Q3 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Slide Deck

Trump’s Secret Manhattan Project (Ad)

On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.

Click here and I’ll show you exactly how to position your money

Embecta Earnings Headlines

Embecta (NASDAQ:EMBC) and PAVmed (NASDAQ:PAVM) Critical Analysis
Contrasting Embecta (NASDAQ:EMBC) and QHSLab (OTCMKTS:USAQ)
DeFi Coin on Verge of Breakout!
[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off!
BTIG upgrades Embecta Corporation (EMBC) to a Buy
See More Embecta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Embecta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Embecta and other key companies, straight to your email.

About Embecta

Embecta (NASDAQ:EMBC), a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

View Embecta Profile

More Earnings Resources from MarketBeat

Upcoming Earnings